Eli Lilly and Company

Tweet this page
<
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
>
Registration as it was on 13 May 2022
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

900,000€ - 999,999€

Financial year: Jan 2021 - Dec 2021

Lobbyists (Full time equivalent)

2 Fte (5)

Lobbyists with EP accreditation

5

High-level Commission meetings

16

Lobbying Costs over the years

  • Info

    Eli Lilly and Company   (Lilly)

    EU Transparency Register

    04657143399-39 First registered on 02 Apr 2010

    Goals / Remit

    Lilly is a leading innovative biopharmaceutical company that unites caring with discovery to make life better for people around the world. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

    Headquartered in the US, Lilly has more than 36,000 employees worldwide, including 20,153 outside the USA. In 2021 global revenue was approx. $28.31 billion, of which c.25% were invested in R&D. Average cost to discover and develop a new drug: $2.6 billion. Average length of time from discovery to patient: 10 years.

    ( https://investor.lilly.com/financials.cfm )

    Main EU files targeted

    EU Pharmaceutical Strategy, EU pharmaceutical legislation, Intellectual Property Rights and incentives - including Orphan Medicinal Products, Paediatric medicines and Anti-Microbial Resistance (AMR), Free Trade Agreements - EU/US, EU/UK, EU Beating Cancer Plan, EU HTA Regulation, EU Green Deal, Pharmaceuticals in the environment (PIE), the Circular Economy, Climate change, Energy taxes, European Chemicals Agency (ECA), REACH, Industrial strategy, Competition law, Horizon Europe, Innovative Healthcare Initiative (IHI), European Medicines Agency (EMA), Clinical Trials Regulation, Medical Devices Regulation, Falsified Medicines Directive, Cross-border Healthcare Directive, Data Protection Regulation, Public Procurement Directive, Transparency Directive, Artificial intelligence, Digital / Digital health. Other policy areas of interest include Innovation, Research and Development, Public-Private Partnerships, Mergers and acquisitions, Life sciences, Biopharmaceuticals, Manufacturing including Active Pharmaceutical Ingredients (API), Health outcomes, Real world evidence, Pricing, reimbursement and market access to medicines, Alzheimer's research, cancer, diabetes, immunology, pain, healthcare sustainability, global health pandemics, clinical trials transparency, patient advocacy group payments, transfers of value to healthcare professionals and healthcare organisations.

    Address

    Head Office
    Lilly Corporate Center Indianapolis Indiana
    Indianapolis 46285
    UNITED STATES
    EU Office
    Rue du Marquis 1/4B Markiesstraat
    Brusselles / Brussel B-1000
    BELGIUM

    Website

  • People

    Total lobbyists declared

    5

    Employment timeLobbyists
    50%3
    25%2

    Lobbyists (Full time equivalent)

    2

    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    5 accreditations were / are live (in bold) for the selected state of 27 Nov 2022

    Name Start date End Date
    Mr Goncalo FERREIRA-PINTO-MENDES 24 Nov 2022 23 Nov 2023
    Mr Pierluca ARIETTI 19 Nov 2022 17 Nov 2023
    Mr Maurizio GUIDI 19 Nov 2022 17 Nov 2023
    Ms Sonia Ujupan 24 Sep 2022 22 Sep 2023
    Mr Goncalo PINTO MENDES 20 Oct 2021 19 Oct 2022
    Ms Doris Schernhammer 13 May 2021 12 May 2022
    Ms Aoife Gallagher 11 May 2021 10 May 2022
    Ms Sonia Ujupan 05 Mar 2021 04 Mar 2022
    Mr Gerd KRAH 27 Feb 2020 26 Feb 2021
    Ms Sonia Ujupan 05 Feb 2020 04 Feb 2021
    Ms Aoife Gallagher 03 Oct 2019 02 Oct 2020
    Ms Arantzazu MUGICA GOICOECHEA 30 Mar 2019 31 Mar 2020
    Ms Sonia Ujupan 28 Nov 2018 28 Nov 2019
    Ms Doris Schernhammer 10 Nov 2018 08 Nov 2019
    Mr Davide RUFFO 09 Nov 2018 08 Nov 2019
    Ms Aoife Gallagher 24 May 2018 23 May 2019
    Ms Sonia Ujupan 13 Nov 2017 10 Nov 2018
    Ms Doris Schernhammer 01 Nov 2017 30 Oct 2018
    Ms Doris Schernhammer 22 Nov 2016 18 Nov 2017
    Ms Aoife Gallagher 22 Nov 2016 18 Nov 2017
    Ms Sonia Ujupan 16 Nov 2016 14 Nov 2017
    Ms Elisa Irlandese 15 Sep 2016 13 Sep 2017
    Mr Olivier ESPEISSE 14 Jan 2016 13 Jan 2017
    Ms Doris Schernhammer 13 Jan 2016 12 Jan 2017
    Ms Athanasia Kanli 17 Nov 2015 12 Nov 2016
    Ms Aoife Gallagher 23 Jul 2015 20 Jul 2016
    Ms Doris Schernhammer 27 Jan 2015 23 Jan 2016
    Ms Athanasia Kanli 10 Dec 2014 08 Dec 2015
    Mr Alexander Josef ANTON 04 Apr 2013 22 Mar 2014
    Mr Hugh Thomas PULLEN 26 Mar 2013 22 Mar 2014
    Mr Alexander Josef ANTON 24 Feb 2012 28 Feb 2013
    Mr Hugh Thomas PULLEN 24 Feb 2012 28 Feb 2013

    Complementary Information

    Note: 3 colleagues are full-time engaged in the Brussels office, and 2 outside Brussels, and will spend approx 25% - 50% of their time on relevant EU affairs. A few other colleagues whereas spend a fraction of their time (<5%).

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    Companies & groups

  • Networking

    Affiliation

    Eli Lilly and Company is a member of the following associations and bodies: EFPIA, EuropaBio, AmChamEU, Digital Europe, American European Community Association, Trans-Atlantic Policy Network, Kangaroo Group, Belgian Brain Council, ABC Global Alliance, Transforming Breast Cancer Together and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Promotes their own interests or the collective interests of their members

    Closed financial year

    Jan 2021 - Dec 2021

    Lobbying costs for closed financial year

    900,000€ - 999,999€

    Major contributions in closed year

    None declared

    Intermediaries for closed year

    NameAmount
    covington & burling llp 25,000€ - 49,999€
    fleishman-hillard 50,000€ - 99,999€
    rud pedersen public affairs brussels 100,000€ - 199,999€

    Intermediaries for current year

    Name
    fleishman-hillard
    rud pedersen public affairs brussels

    Closed year Costs

    900,000€ - 999,999€

    Other financial info

    None declared

  • EU Structures

    Groups (European Commission)

    none

    Groups (European Parliament)

    N/A

    Other activities

    None declared

  • Meetings

    Meetings

    16 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't publish information about such meetings. All information below comes from European Commission web pages.

Download this datacard